CERE-120: AAV2-NTN

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	1

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00252850 (ClinicalTrials.gov)	June 2005	11/11/2005	Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease	A Phase I, Open-Label Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin[NTN] to ...	Parkinson's Disease	Genetic: CERE-120: AAV2-NTN	Sangamo Therapeutics	Ceregene	Completed	35 Years	75 Years	All	12	Phase 1	United States

First Previous1Next Last